Resistance of human astrocytoma cells to apoptosis induced by mitochondria-damaging agents: Possible implications for anticancer therapy

被引:27
作者
Ceruti, S [1 ]
Mazzola, A [1 ]
Abbracchio, MP [1 ]
机构
[1] Univ Milan, Sch Pharm, Dept Pharmacol Sci, Lab Mol & Cellular Pharmacol Purinerg Transmiss, I-20133 Milan, Italy
关键词
D O I
10.1124/jpet.105.085340
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The success of anticancer chemotherapy is often hampered by resistance to apoptosis, which may depend on defects in intracellular cell death pathways. Characterizing the alterations of these pathways is a prerequisite for developing alternative and effective antitumoral strategies. Here, we investigated the susceptibility of a human astrocytoma cell line, ADF, to apoptotic cell death induced by mitochondria-damaging agents. Neither the anticancer agent betulinic acid nor the "mitochondriotropic" poisons 2-deoxy-D-ribose and potassium cyanide induced apoptosis of these cells, despite induction of highly significant mitochondrial depolarization, eventually resulting in necrotic death. Resistance to apoptosis was not due to presence of the multidrug re-sistance pump or to impaired expression of caspase-8, caspase-9, or "executioner" caspase-3. Cloning of caspase-9 revealed the presence of full-length caspase-9 alpha and a short variant (caspase-9 beta), which, in other tumors, acts as a dominant negative of the long isoform. All analyzed clones showed a point mutation in the prodomain region that is known to interact with mitochondria-released factors. Thus, in these human astrocytoma cells, mitochondria-damaging agents induce a regulated form of mitochondrial-dependent necrotic cell death (oncosis). Resistance to apoptosis is due to an intrinsic defect of caspase-9, leading to inhibition of enzyme activation and/or impaired interaction with proteins released from depolarized mitochondria. These results may have implications for developing strategies aimed at overcoming tumor resistance to chemotherapy.
引用
收藏
页码:825 / 837
页数:13
相关论文
共 42 条
[1]
Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK [J].
Allan, LA ;
Morrice, N ;
Brady, S ;
Magee, G ;
Pathak, S ;
Clarke, PR .
NATURE CELL BIOLOGY, 2003, 5 (07) :647-U45
[2]
Characterization of a novel isoform of capase-9 that inhibits apoptosis [J].
Angelastro, JM ;
Moon, NY ;
Liu, DX ;
Yang, AS ;
Greene, LA ;
Franke, TF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) :12190-12200
[3]
CLADRIBINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC POTENTIAL IN HEMATOLOGICAL MALIGNANCIES [J].
BRYSON, HM ;
SORKIN, EM .
DRUGS, 1993, 46 (05) :872-894
[4]
Ceruti S, 1997, J NEUROSCI RES, V47, P372, DOI 10.1002/(SICI)1097-4547(19970215)47:4<372::AID-JNR2>3.0.CO
[5]
2-B
[6]
A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2′-deoxy-adenosine (Cladribine) and 2-chloro-adenosine in human astrocytoma cells [J].
Ceruti, S ;
Beltrami, E ;
Matarrese, P ;
Mazzola, A ;
Cattabeni, F ;
Malorni, W ;
Abbracchio, MP .
MOLECULAR PHARMACOLOGY, 2003, 63 (06) :1437-1447
[7]
Ceruti S, 2000, J NEUROSCI RES, V60, P388, DOI 10.1002/(SICI)1097-4547(20000501)60:3<388::AID-JNR14>3.0.CO
[8]
2-V
[9]
Mitochondrion as a novel target of anticancer chemotherapy [J].
Costantini, P ;
Jacotot, E ;
Decaudin, D ;
Kroemer, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (13) :1042-1053
[10]
Apoptosis pathways in cancer and cancer therapy [J].
Debatin, KM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (03) :153-159